Facebook advertising for recruitment of midlife women with bothersome vaginal symptoms: A pilot study.


Journal

Clinical trials (London, England)
ISSN: 1740-7753
Titre abrégé: Clin Trials
Pays: England
ID NLM: 101197451

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 6 5 2019
medline: 1 9 2020
entrez: 7 5 2019
Statut: ppublish

Résumé

The MsFLASH (Menopause Strategies: Finding Lasting Answers for Symptoms and Health) Network recruited into five randomized clinical trials (n = 100-350) through mass mailings. The fifth trial tested two interventions for postmenopausal vulvovaginal symptoms (itching, pain, irritation, dryness, or pain with sex) and thus required a high level of sensitivity to privacy concerns. For this trial, in addition to mass mailings we pilot tested a social media recruitment approach. We aimed to evaluate the feasibility of recruiting healthy midlife women with bothersome vulvovaginal symptoms to participate in the Vaginal Health Trial through Facebook advertising. As part of a larger advertising campaign that enrolled 302 postmenopausal women for the 12-week randomized, double-blind, placebo-controlled Vaginal Health Trial from April 2016 to February 2017, Facebook advertising was used to recruit 25 participants. The target population for recruitment by mailings and by Facebook ads included women aged 50-70 years and living within 20 miles of study sites in Minneapolis, MN and Seattle, WA. Design of recruitment letters and Facebook advertisements was informed by focus group feedback. Facebook ads were displayed in the "newsfeed" of targeted users and included a link to the study website. Response rates and costs are described for both online ads and mailing. Facebook ads ran in Minneapolis for 28 days and in Seattle for 15 days, with ads posted and removed from the site as needed based on clinic flow and a set budget limit. Our estimated Facebook advertising reach was over 200,000 women; 461 women responded and 25 were enrolled at a cost of US$14,813. The response rate per estimated reach was 0.22%; costs were US$32 per response and US$593 per randomized participant. The social media recruitment results varied by site, showing greater effectiveness in Seattle than in Minneapolis. We mailed 277,000 recruitment letters; 2166 women responded and 277 were randomized at a cost of US$98,682. The response rate per letter sent was 0.78%; costs were US$46 per response and US$356 per randomized participant. Results varied little across sites. Recruitment to a clinical trial testing interventions for postmenopausal vaginal symptoms is feasible through social media advertising. Variability in observed effectiveness and costs may reflect the small sample sizes and limited budget of the pilot recruitment study.

Sections du résumé

BACKGROUND
The MsFLASH (Menopause Strategies: Finding Lasting Answers for Symptoms and Health) Network recruited into five randomized clinical trials (n = 100-350) through mass mailings. The fifth trial tested two interventions for postmenopausal vulvovaginal symptoms (itching, pain, irritation, dryness, or pain with sex) and thus required a high level of sensitivity to privacy concerns. For this trial, in addition to mass mailings we pilot tested a social media recruitment approach. We aimed to evaluate the feasibility of recruiting healthy midlife women with bothersome vulvovaginal symptoms to participate in the Vaginal Health Trial through Facebook advertising.
METHODS
As part of a larger advertising campaign that enrolled 302 postmenopausal women for the 12-week randomized, double-blind, placebo-controlled Vaginal Health Trial from April 2016 to February 2017, Facebook advertising was used to recruit 25 participants. The target population for recruitment by mailings and by Facebook ads included women aged 50-70 years and living within 20 miles of study sites in Minneapolis, MN and Seattle, WA. Design of recruitment letters and Facebook advertisements was informed by focus group feedback. Facebook ads were displayed in the "newsfeed" of targeted users and included a link to the study website. Response rates and costs are described for both online ads and mailing.
RESULTS
Facebook ads ran in Minneapolis for 28 days and in Seattle for 15 days, with ads posted and removed from the site as needed based on clinic flow and a set budget limit. Our estimated Facebook advertising reach was over 200,000 women; 461 women responded and 25 were enrolled at a cost of US$14,813. The response rate per estimated reach was 0.22%; costs were US$32 per response and US$593 per randomized participant. The social media recruitment results varied by site, showing greater effectiveness in Seattle than in Minneapolis. We mailed 277,000 recruitment letters; 2166 women responded and 277 were randomized at a cost of US$98,682. The response rate per letter sent was 0.78%; costs were US$46 per response and US$356 per randomized participant. Results varied little across sites.
CONCLUSION
Recruitment to a clinical trial testing interventions for postmenopausal vaginal symptoms is feasible through social media advertising. Variability in observed effectiveness and costs may reflect the small sample sizes and limited budget of the pilot recruitment study.

Identifiants

pubmed: 31055949
doi: 10.1177/1740774519846862
pmc: PMC6742530
mid: NIHMS1526613
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

476-480

Subventions

Organisme : NIA NIH HHS
ID : R01 AG048209
Pays : United States

Références

Menopause. 2010 May-Jun;17(3):480-6
pubmed: 20032798
Menopause. 2013 Jun;20(6):623-30
pubmed: 23361170
Addict Behav. 2013 Oct;38(10):2473-6
pubmed: 23770645
PLoS One. 2014 Mar 26;9(3):e92744
pubmed: 24671210
Menopause. 2016 Mar;23(3):243-56
pubmed: 26731686
Vaccine. 2017 Jun 14;35(27):3498-3505
pubmed: 28526330
AIDS Behav. 2017 Nov;21(11):3141-3153
pubmed: 28528463
Clin Trials. 2018 Apr;15(2):130-138
pubmed: 29361843
JAMA Intern Med. 2018 May 1;178(5):681-690
pubmed: 29554173
Clin Trials. 2018 Oct;15(5):522-523
pubmed: 29952243

Auteurs

Katherine A Guthrie (KA)

Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Bette Caan (B)

Division of Research, Kaiser Permanente of Northern California, Oakland, CA, USA.

Susan Diem (S)

Departments of Medicine and Epidemiology & Community Health, University of Minnesota, Minneapolis, MN, USA.

Kristine E Ensrud (KE)

Departments of Medicine and Epidemiology & Community Health, University of Minnesota, Minneapolis, MN, USA.
Department of Medicine, Minneapolis VA Health Care System, Minneapolis, MN, USA.

Sharon R Greaves (SR)

Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Joseph C Larson (JC)

Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Katherine M Newton (KM)

Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.

Susan D Reed (SD)

Department of Obstetrics & Gynecology, University of Washington, Seattle, WA, USA.

Andrea Z LaCroix (AZ)

Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH